# REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)

Study · id `cardio:ct-nct01483560` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01483560](<https://clinicaltrials.gov/study/NCT01483560>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01483560

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 493 participants.

## Technical summary

Registry record NCT01483560. Randomized; triple masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2017-03-19 (actual). Results posted on 2019-06-03.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 493 participants (enrolled count; ClinicalTrials.gov record NCT01483560, source copy `cardio:ctgov-nct01483560-2019-06-19`, retrieved 2026-10-26)
- Start date: 2011-12 (registry gives no type) (ClinicalTrials.gov record NCT01483560, source copy `cardio:ctgov-nct01483560-2019-06-19`, retrieved 2026-10-26)
- Primary completion: 2017-03-19 (actual) (ClinicalTrials.gov record NCT01483560, source copy `cardio:ctgov-nct01483560-2019-06-19`, retrieved 2026-10-26)
- Completion: 2017-04-18 (actual) (ClinicalTrials.gov record NCT01483560, source copy `cardio:ctgov-nct01483560-2019-06-19`, retrieved 2026-10-26)
- Results first posted: 2019-06-03 (ClinicalTrials.gov record NCT01483560, source copy `cardio:ctgov-nct01483560-2019-06-19`, retrieved 2026-10-26)
- Countries: Australia; Canada; Denmark; Netherlands; United Kingdom (ClinicalTrials.gov record NCT01483560, source copy `cardio:ctgov-nct01483560-2019-06-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01483560-2019-06-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: REducing With MetfOrmin Vascular Adverse Lesions in Type 1 Diabetes (REMOVAL)
- Acronym: REMOVAL
- Condition: Diabetes Mellitus, Type 1
- Intervention (Drug): Metformin
- Intervention (Drug): Placebo
- Lead sponsor: University of Glasgow
- Lead sponsor class: OTHER
- Collaborator: NHS Greater Glasgow and Clyde
- Collaborator class: OTHER
- Collaborator: Juvenile Diabetes Research Foundation
- Collaborator class: OTHER
- Collaborator: Imperial College London
- Collaborator class: OTHER
- Collaborator: University of Wisconsin, Madison
- Collaborator class: OTHER
- Collaborator: University of Dundee
- Collaborator class: OTHER
- Collaborator: Merck Serono S.A., Geneva
- Collaborator class: INDUSTRY
- Collaborator: Itamar-Medical, Israel
- Collaborator class: INDUSTRY
- Collaborator: University of Western Ontario, Canada
- Collaborator class: OTHER
- Collaborator: University of Melbourne
- Collaborator class: OTHER
- Collaborator: Steno Diabetes Center Copenhagen
- Collaborator class: OTHER
- Collaborator: Maastricht University Medical Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry condition terms include this condition: Type 1 diabetes (`core:type-1-diabetes`)
- Registry lists this organization as the lead sponsor: University of Glasgow (`cardio:org-university-of-glasgow`)
- Registry lists this organization as a collaborator: NHS Greater Glasgow and Clyde (`cardio:org-nhs-greater-glasgow-and-clyde`)
- Registry lists this organization as a collaborator: Juvenile Diabetes Research Foundation (`cardio:org-juvenile-diabetes-research-foundation`)
- Registry lists this organization as a collaborator: Imperial College London (`cardio:org-imperial-college-london`)
- Registry lists this organization as a collaborator: University of Wisconsin, Madison (`cardio:org-university-of-wisconsin-madison`)
- Registry lists this organization as a collaborator: University of Dundee (`cardio:org-university-of-dundee`)
- Registry lists this organization as a collaborator: University of Melbourne (`cardio:org-university-of-melbourne`)
- Registry lists this organization as a collaborator: Steno Diabetes Center Copenhagen (`cardio:org-steno-diabetes-center-copenhagen`)
- Registry lists this organization as a collaborator: Maastricht University Medical Center (`cardio:org-maastricht-university-medical-center`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial (`cardio:pubmed-28615149`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 82ddd3452dad7d834adfc3363dc909ab19d850e810ab5028a7d816b1c5fc73bd
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
